Preclinical model of recurrent human cutaneous melanoma with CD20 overexpression for discovery and study of targeted therapy

A preclinical model of human cutaneous melanoma with CD20 overexpression in relapsed cells addresses the lack of suitable models for studying CD20 subpopulation formation during vemurafenib treatment, facilitating the evaluation of anti-CD20 drugs for recurrent melanoma therapy.

RU2865715C1Active Publication Date: 2026-07-08FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ MEDITSINSKIJ ISSLEDOVATELSKIJ TSENTR ONKOLOGII IMENI N N BLOKHINA MINISTSTVA ZDRAVOOKHRANENIYA ROSSIJSKOJ FEDERATSII FGBU NMITS ONKOLOGII IM N N BLOKHINA MINZDRAVA ROSSII
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
RU2025108728
Authority / Receiving Office
RU · RU
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-04-08
Publication Date
2026-07-08
Estimated Expiration
2045-04-08

AI Technical Summary

Technical Problem

The lack of an appropriate in vivo model to study the patterns of CD20 subpopulation formation during treatment with vemurafenib in metastatic cutaneous melanoma (mCM) hinders the development of combination therapies involving BRAF inhibitors and anti-CD20 drugs like rituximab.

Method used

A preclinical model of human cutaneous melanoma with overexpression of CD20 in relapsed cells is created using the MelCher5k/BRAF xenograft adapted to grow in immunodeficient Balb/c nude mice, allowing for the characterization of CD20 expression and potential therapeutic effects of vemurafenib.

Benefits of technology

The model provides a reliable system to study CD20 expression dynamics and potential therapeutic responses, enabling the evaluation of anti-CD20 drugs like rituximab for treating recurrent mCM post-vemurafenib therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000003
    Figure 00000003
  • Figure 00000004
    Figure 00000004
Patent Text Reader

Abstract

FIELD: biotechnology; medicine.SUBSTANCE: use of a subcutaneous xenograft of recurrent human skin melanoma MelCher5k / BRAF+ with CD20 hyperexpression, stably growing in immunodeficient Balb / c nude mice, for preclinical search and study of targeted therapy under the control of CD20 expression after treatment with vemurafenib.EFFECT: possibility of using the model to search for new anti-melanoma agents for the treatment of progressive melanoma.1 cl, 4 dwg, 1 tbl
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • METHOD OF PRODUCTION OF SUBDERMAL XENOGRAFTS OF CELL LINE OF PEOPLE SKIN MELANOMA mel Cher WITH MUTATION V600E BRAF FOR PRECLINICAL STUDY OF ANTINEOPLASTIC TARGETED AGENTS

    RU2572569C1